cangrelor tetrasodium

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cangrelor tetrasodium 是一种可逆性、选择性的血小板 P2Y12 拮抗剂，具有快速、有效的抗血小板作用。cangrelor 是一种非脓毒性 GPR17 拮抗剂，通过抑制小鼠巨噬细胞炎症来部分缓解肺纤维化。

Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects.cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10 mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs.

——

——

——

Cell Cycle/DNA Damage

GPR

GPR17

——

——

163706-36-3

864.29

C17H21Cl2F3N5Na4O12P3S2

>98% (HPLC)

In Vitro:?H2O : 125 mg/mL (144.63 mM)

[Na+].[Na+].[Na+].[Na+].CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years